Jeff Fairman, VP, Research at Vaxcyte, Inc. (PCVX), sold 9,361 shares at $26.16 ($245K) on 2021-09-27, disclosed to the SEC on 2021-09-29.
Open-market sale of $245k PCVX by VP, Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.16 | 4,611 | $121K | 49.2% |
| 2 | $26.16 | 4,611 | $121K | 49.2% |
| 3 | $26.47 | 139 | $4K | 1.5% |
| Total | $26.16 avg | 9,361 | $245K | 100% |
| Filing → |
| PCVX | SELL | 2022-09-07 | $257K | — | Filing → |
| PCVX | SELL | 2022-08-05 | $384K | — | Filing → |
| PCVX | SELL | 2022-05-24 | $105K | — | Filing → |